v**e
发帖数: 8422 | 1 【 以下文字转载自 Military 讨论区 】
发信人: StMicheal (archangel), 信区: Military
标 题: 华尔街日报报道科兴疫苗有效率包括所有极轻症50.4%
发信站: BBS 未名空间站 (Tue Jan 12 12:31:16 2021, 美东)
https://www.wsj.com/articles/chinas-sinovac-covid-19-vaccine-is-50-4-in-late
-stage-brazil-trials-11610470581
Chinese Covid-19 Vaccine Is Far Less Effective Than Initially Touted in
Brazil
Late-state testing results of Sinovac’s shot were almost 30 percentage
points lower than previously announced, as concerns grow over the study’s
transparency
包括了所有“very mild” cases of Covid-19 and required no medical assistance
以后，50.4%。
不知道是不是核酸阳性是标准。
这个很搞。这个case定义不知道和辉瑞moderna一样不一样。
Brazilian researchers testing China’s Sinovac Vaccine said Tuesday that
full data showed it to be 50.38% effective against Covid-19 in late-stage
trials, almost 30 percentage points lower than previously announced, as
concerns grow over the study’s transparency.
The São Paulo-based Butantan Institute said last week that late-stage
trials had shown the CoronaVac vaccine to be between 78% and 100% effective,
offering total protection against severe cases of the disease.
However, after rising pressure from scientists, some of whom accused the
trial’s organizers of misleading the public, Butantan said those rates only
included volunteers who suffered mild to severe cases of Covid-19. When
data from all volunteers is considered, including those who contracted “
very mild” cases of Covid-19 and required no medical assistance, the total
efficacy rate falls to 50.38%, Butantan said Tuesday.
Despite having one of the lowest efficacy rates for any new coronavirus
vaccine, CoronaVac is still more effective than some flu vaccines and can be
stored cheaply in an ordinary refrigerator, making it a viable option for
developing countries, public health experts said.
However, the piecemeal and unorthodox announcement of CoronaVac’s efficacy
rate, which was first scheduled to be announced last month, risks damaging
the credibility of a vaccine that many Brazilians are already reluctant to
take, doctors said. |
|
